Adeptus Health Inc. (NYSE:ADPT) Receives $84.00 Consensus PT from Brokerages
Shares of Adeptus Health Inc. (NYSE:ADPT) have earned a consensus rating of “Buy” from the ten research firms that are currently covering the stock. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $84.00.
Several equities research analysts have recently weighed in on ADPT shares. JMP Securities reiterated a “buy” rating on shares of Adeptus Health in a research note on Thursday, September 22nd. Goldman Sachs Group Inc. set a $80.00 target price on shares of Adeptus Health and gave the stock a “buy” rating in a research note on Thursday, September 8th. Jefferies Group set a $77.00 target price on shares of Adeptus Health and gave the stock a “buy” rating in a research note on Thursday, September 8th. Finally, Zacks Investment Research downgraded shares of Adeptus Health from a “buy” rating to a “strong sell” rating in a research note on Wednesday, July 13th.
A number of large investors have recently made changes to their positions in the stock. Texas Permanent School Fund increased its stake in shares of Adeptus Health by 94.0% in the first quarter. Texas Permanent School Fund now owns 9,584 shares of the company’s stock worth $532,000 after buying an additional 4,645 shares during the last quarter. Prudential Financial Inc. boosted its position in shares of Adeptus Health by 60.8% in the first quarter. Prudential Financial Inc. now owns 125,932 shares of the company’s stock worth $6,995,000 after buying an additional 47,632 shares during the period. Franklin Resources Inc. boosted its position in shares of Adeptus Health by 10.0% in the first quarter. Franklin Resources Inc. now owns 700,061 shares of the company’s stock worth $38,881,000 after buying an additional 63,912 shares during the period. BlackRock Fund Advisors boosted its position in shares of Adeptus Health by 10.2% in the first quarter. BlackRock Fund Advisors now owns 671,316 shares of the company’s stock worth $37,285,000 after buying an additional 62,193 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Adeptus Health by 11.1% in the first quarter. JPMorgan Chase & Co. now owns 31,405 shares of the company’s stock worth $1,744,000 after buying an additional 3,130 shares during the period.
Shares of Adeptus Health (NYSE:ADPT) opened at 39.65 on Thursday. The firm’s 50-day moving average price is $41.22 and its 200 day moving average price is $52.17. The stock has a market capitalization of $648.28 million, a price-to-earnings ratio of 6.04 and a beta of 0.96. Adeptus Health has a 1-year low of $35.33 and a 1-year high of $90.71.
Adeptus Health (NYSE:ADPT) last released its quarterly earnings data on Thursday, July 21st. The company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.03. Adeptus Health had a net margin of 22.99% and a return on equity of 14.74%. The company earned $100.20 million during the quarter, compared to analyst estimates of $93.92 million. During the same quarter in the prior year, the company earned $0.44 EPS. The business’s revenue was up 36.2% on a year-over-year basis. Equities research analysts expect that Adeptus Health will post $2.46 earnings per share for the current fiscal year.
Adeptus Health Company Profile
Adeptus Health Inc is a patient-centered healthcare company. The Company is engaged in providing emergency medical care through a network of independent freestanding emergency rooms in the United States and partnerships with various healthcare systems. The Company has approximately 80 freestanding facilities and over two licensed general hospitals.
Receive News & Stock Ratings for Adeptus Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adeptus Health Inc. and related stocks with our FREE daily email newsletter.